---
title: Alpha synuclein detects early Parkinson
nct_id: NCT06232772
status: RECRUITING
sponsor: Yousheng Xiao
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06232772"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06232772"
last_fetched: "2026-05-10T14:04:55.316Z"
source: "Parkinson's Pathways (curated)"
---
# Alpha synuclein detects early Parkinson

**Goal (in five words):** Alpha synuclein detects early Parkinson

**Official Title:** Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease:An Observational, Multicenter, Non-Randomized Controlled Study

**Trial ID:** [NCT06232772](https://clinicaltrials.gov/study/NCT06232772)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Yousheng Xiao
- **Target Enrollment:** 600 participants
- **Start Date:** 2024-03-31
- **Completion Date:** 2026-06
- **Conditions:** Parkinson's Disease
- **Interventions:** α- Synuclein Ultrafine Fluorescence Detection Method
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

The goal is to find early, reliable markers that can diagnose Parkinson's sooner and help tell Parkinson's apart from similar conditions like MSA and PSP so people get the right care faster. Researchers are using an ultrafine fluorescence technique to detect misfolded alpha-synuclein, the protein that clumps in Parkinson's, by making those tiny aggregates light up in biological samples; because it is observational the test does not change treatments or interact with levodopa. About 600 adults aged 18 to 80 will be enrolled, including people with clinically confirmed or probable early-stage PD (Hoehn and Yahr ≤ 2.5), plus comparison groups with MSA and PSP and healthy matched controls. People with secondary Parkinsonism from drugs or vascular causes, severe cognitive impairment, or other major neurodegenerative diseases are not eligible.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Patients with clinically defined or probable PD：According to the 2015 MDS diagnostic criteria, patients diagnosed with "clinically confirmed PD" regardless of age, gender, and meeting Hoehn\&Yahr staging ≤ 2.5 were included as case group one, which met \[Parkinson's syndrome+at least two supportive criteria+no absolute exclusion criteria\]
* Patients with clinically probable PD：According to the 2015 MDS diagnostic criteria, patients diagnosed with "clinically probable PD", regardless of age or gender, and meeting Hoehn\&Yahr staging ≤ 2.5 were included as case group two, i.e. patients who met \[Parkinson's syndrome+no absolute exclusion criteria+1/2 supportive criteria+1/2 warning signs\]
* MSA group：Adult onset (\>30 years old), sporadic and progressive development, and possessing the following characteristics: 1 Has one of the following two conditions: ① Parkinson's syndrome with levodopa adverse response (bradykinesia, accompanied by muscle rigidity, tremors, or postural instability), ② cerebellar dysfunction: gait ataxia, accompanied by cerebellar articulation disorders, limb ataxia, or cerebellar eye movement disorders; 2. At least one manifestation of autonomic dysfunction is present: ① urinary incontinence (inability to control bladder urination, male with erectile dysfunction), ② orthostatic hypotension (a decrease in systolic blood pressure of ≥ 30mmHg and/or diastolic blood pressure of ≥ 15mmHg after standing for 3 minutes).
* PSP group：Clinical diagnosis and likely PSP included in the Chinese progressive supranuclear palsy clinical diagnostic criteria developed by the Parkinson's disease and motor disorders group of the Neurology Branch of the Chinese Medical Association in 2016;
* Healthy subjects：Healthy population matched with age and gender in the experimental group In addition to the selected patients, a study will also be conducted on patient data in the reference database of the proposing institution.

Exclusion Criteria:

* Patients who do not consent to study participation
* Secondary Parkinson's syndrome caused by vascular factors, drugs, etc
* Severe cognitive impairment, AD, amyotrophic lateral sclerosis and other neurodegenerative diseases
```

## Locations (1)

- Guangxi Medical University, Nanning, Guangxi, China _(22.8167, 108.3167)_
  - Yousheng Xiao, professor — (CONTACT) — +86 15177196935 — xys135@126.com
  - Yanzi Bao, postgraduate — (CONTACT) — +86 17673172378 — deer0522@163.com
  - Yousheng Xiao, professor — (PRINCIPAL_INVESTIGATOR)
  - Pingyi Xu, professor — (SUB_INVESTIGATOR)
  - Zhong Pei, professor — (SUB_INVESTIGATOR)
  - Yuyin Hu, assoc. Prof. — (SUB_INVESTIGATOR)
  - Meiling Chen, assoc. Prof. — (SUB_INVESTIGATOR)
  - Li Wang, Ph.D. — (SUB_INVESTIGATOR)
  - Huang Huaxin, postgraduate — (SUB_INVESTIGATOR)
  - Yanzi Bao, postgraduate — (SUB_INVESTIGATOR)

## Central Contacts

- Yousheng Xiao, professor — (CONTACT) — +86 15177196935 — xys135@126.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06232772*  
*HTML version: https://parkinsonspathways.com/trial/NCT06232772*  
*Source data: https://clinicaltrials.gov/study/NCT06232772*